Chinese biotechnology company Immunochina Pharmaceuticals has raised a RMB$140 million (US$20.4 million) series C round of financing led by a syndicate of Chinese and international investors, according to a statement released on January 22.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?